Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.61 |
| ▸ | PTPRA | P18433 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 6/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665787 | 0.89 | CTSS (0.67) | PTPN1PTPRACTSSCTSKPLG | |
| SCHEMBL21318569 | 0.89 | CTSS (0.67) | PTPN1PTPRACTSSCTSKPLG | |
| SCHEMBL7064457 | 0.89 | CTSK (0.69) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL31628753 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL31628751 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL31628776 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL31628716 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL3174229 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL31628718 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL | |
| SCHEMBL28520727 | 0.88 | PTPN1 (0.68) | PTPN1PTPRACTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885PTPRA 11/4885CTSS 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.